2014 Q1 Form 10-Q Financial Statement

#000120677415001584 Filed on May 05, 2015

View on sec.gov

Income Statement

Concept 2014 Q1
Revenue $308.3K
YoY Change -56.4%
Cost Of Revenue $1.040M
YoY Change -37.72%
Gross Profit -$730.0K
YoY Change -23.96%
Gross Profit Margin -236.75%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $449.8K
YoY Change -29.32%
% of Gross Profit
Depreciation & Amortization $6.075K
YoY Change -41.14%
% of Gross Profit
Operating Expenses $1.487M
YoY Change -35.47%
Operating Profit -$1.179M
YoY Change -27.04%
Interest Expense $10.00K
YoY Change 0.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.170M
YoY Change -26.42%
Income Tax
% Of Pretax Income
Net Earnings -$1.170M
YoY Change -27.22%
Net Earnings / Revenue -379.44%
Basic Earnings Per Share
Diluted Earnings Per Share -$50.61K
COMMON SHARES
Basic Shares Outstanding 23.11M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.18M
YoY Change -20.9%
Cash & Equivalents $5.098M
Short-Term Investments $5.080M
Other Short-Term Assets $80.00K
YoY Change -11.11%
Inventory
Prepaid Expenses
Receivables $860.4K
Other Receivables $0.00
Total Short-Term Assets $11.12M
YoY Change -19.15%
LONG-TERM ASSETS
Property, Plant & Equipment $101.5K
YoY Change 69.23%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $33.57K
YoY Change 67.84%
Total Long-Term Assets $135.1K
YoY Change 50.11%
TOTAL ASSETS
Total Short-Term Assets $11.12M
Total Long-Term Assets $135.1K
Total Assets $11.25M
YoY Change -18.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $138.4K
YoY Change -18.6%
Accrued Expenses $201.5K
YoY Change 11.93%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $396.1K
YoY Change -26.65%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $396.1K
Total Long-Term Liabilities $0.00
Total Liabilities $400.0K
YoY Change -25.93%
SHAREHOLDERS EQUITY
Retained Earnings -$94.47M
YoY Change
Common Stock $105.3M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.86M
YoY Change
Total Liabilities & Shareholders Equity $11.25M
YoY Change -18.7%

Cashflow Statement

Concept 2014 Q1
OPERATING ACTIVITIES
Net Income -$1.170M
YoY Change -27.22%
Depreciation, Depletion And Amortization $6.075K
YoY Change -41.14%
Cash From Operating Activities -$810.0K
YoY Change 44.64%
INVESTING ACTIVITIES
Capital Expenditures $43.25K
YoY Change 288.65%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$40.00K
YoY Change 300.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 80.00K
YoY Change
NET CHANGE
Cash From Operating Activities -810.0K
Cash From Investing Activities -40.00K
Cash From Financing Activities 80.00K
Net Change In Cash -770.0K
YoY Change 35.09%
FREE CASH FLOW
Cash From Operating Activities -$810.0K
Capital Expenditures $43.25K
Free Cash Flow -$853.2K
YoY Change 49.4%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q1 us-gaap Long Term Investments
LongTermInvestments
1505179 USD
CY2014Q4 us-gaap Long Term Investments
LongTermInvestments
1503525 USD
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
449813 USD
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
1486973 USD
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1178626 USD
CY2014Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
8641 USD
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-1169985 USD
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23117229 shares
CY2014Q1 us-gaap Revenues
Revenues
308347 USD
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1037160 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-806202 USD
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
43245 USD
CY2014Q1 us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
1040 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-44285 USD
CY2015Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
245873 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
245873 USD
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-768199 USD
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5097924 USD
CY2014Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
82288 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
82288 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1109878 USD
CY2015Q1 us-gaap Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Volatility Rate
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate
0.65 pure
CY2014Q1 us-gaap Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Volatility Rate
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate
0.62 pure
CY2015Q1 us-gaap Basis Of Accounting
BasisOfAccounting
<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p align="justify"><font style="text-decoration: underline;"><font style="font-size: 10pt;">Basis of Presentation</font></font><font style="font-size: 10pt;"></font></p> <p align="justify"><font style="font-size: 10pt;">The accompanying unaudited consolidated condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#147;GAAP&#148;) for interim financial information and with the instructions to Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All such adjustments are of a normal recurring nature. Operating results for the three months ended March 31, 2015 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2015. For further information, refer to the consolidated financial statements and footnotes thereto included in the Annual Report on Form 10-K relating to Research Frontiers Incorporated (the &#147;Company&#148;) for the fiscal year ended December 31, 2014.</font></p> </div>
CY2015Q1 us-gaap Nature Of Operations
NatureOfOperations
<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p align="justify"><font style="text-decoration: underline;"><font style="font-size: 10pt;">Business</font></font><font style="font-size: 10pt;"></font></p> <p align="justify" style="color: #000000; font-family: 'Times New Roman'; font-size: medium; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px;"><font size="2">Research Frontiers Incorporated (&#147;Research Frontiers&#148; or the &#147;Company&#148;) operates in a single business segment which is engaged in the development and marketing of technology and devices to control the flow of light. Such devices, often referred to as &#147;light valves&#148; or suspended particle devices (SPDs), use colloidal particles that are either incorporated within a liquid suspension or a film, which is usually enclosed between two sheets of glass or plastic having transparent, electrically conductive coatings on the facing surfaces thereof. At least one of the two sheets is transparent. SPD technology, made possible by a flexible light-control film invented by Research Frontiers, allows the user to instantly and precisely control the shading of glass/plastic manually or automatically. SPD technology has numerous product applications, including: SPD-Smart&#153; windows, sunshades, skylights and interior partitions for homes and buildings; automotive windows; sunroofs, sun-visors, sunshades, rear-view mirrors, instrument panels and navigation systems; aircraft windows; eyewear products; and flat panel displays for electronic products. SPD-Smart light control film is now being developed for, or used in, architectural, automotive, marine, aerospace and appliance applications.</font></p> <p align="justify" style="color: #000000; font-family: 'Times New Roman'; font-size: medium; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px;"><font size="2">The Company has historically utilized its cash and the proceeds from the sale of its investments to fund its research and development of SPD light valves, for marketing initiatives, and for other working capital purposes. The Company's working capital and capital requirements depend upon numerous factors, including the results of research and development activities, competitive and technological developments, the timing and cost of patent filings, and the development of new licensees and changes in the Company's relationships with its existing licensees. The degree of dependence of the Company's working capital requirements on each of the forgoing factors cannot be quantified; increased research and development activities and related costs would increase such requirements; the addition of new licensees may provide additional working capital or working capital requirements, and changes in relationships with existing licensees would have a favorable or negative impact depending on the nature of such changes. There can be no assurance that expenditures will not exceed the anticipated amounts or that additional financing, if required, will be available when needed or, if available, that's its terms will be favorable or acceptable to the Company. Eventual success of the Company and generation of positive cash flow will be dependent upon the commercialization of products using the Company's technology by the Company's licensees and payments of continuing royalties on account thereof. To date, the Company has not generated sufficient revenue from its licensees to fund its operations.</font></p> </div>
CY2015Q1 us-gaap Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate
0.017 pure
CY2014Q1 us-gaap Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate
0.017 pure
CY2015Q1 us-gaap Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1
P8Y10M24D
CY2014Q1 us-gaap Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1
P5Y4M24D
CY2015Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
9500000 USD
CY2015Q1 dei Amendment Flag
AmendmentFlag
false
CY2015Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q1 dei Document Period End Date
DocumentPeriodEndDate
2015-03-31
CY2015Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2015Q1 dei Entity Registrant Name
EntityRegistrantName
RESEARCH FRONTIERS INC
CY2015Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000793524
CY2015Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2015Q1 dei Document Type
DocumentType
10-Q

Files In Submission

Name View Source Status
0001206774-15-001584-index-headers.html Edgar Link pending
0001206774-15-001584-index.html Edgar Link pending
0001206774-15-001584.txt Edgar Link pending
0001206774-15-001584-xbrl.zip Edgar Link pending
exhibit31-1.htm Edgar Link pending
exhibit31-2.htm Edgar Link pending
exhibit32-1.htm Edgar Link pending
exhibit32-2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
refr-20150331.xml Edgar Link completed
refr-20150331.xsd Edgar Link pending
refr-20150331_cal.xml Edgar Link unprocessable
refr-20150331_def.xml Edgar Link unprocessable
refr-20150331_lab.xml Edgar Link unprocessable
refr-20150331_pre.xml Edgar Link unprocessable
refr_10q.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending